Biotek-snakken — Marts 2024
-
Xbrane has received additional subscription
undertakings corresponding to approximately
SEK 18.1 million in the Company's rights issue -
Ja- Ultimovacs ASA (ULTI.OL)
-
Ultimovacs - CEO Carlos de Sousa og Chief Innovation Officer Sara Mangsbo holder præsentation senere i dag hos Redeye. https://www.redeye.se/events/973619/investor-lunch-ultimovacs
-
Calliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO
Calliditas Therapeutics AB
Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas Therapeutics AB (www.calliditas.se)
-
Calliditas: Extended US Tarpeyo brand protection
"Our base case (SEK 270)"
"The extended exclusivity period makes our base case even more conservative. We are not making any positive revisions at this stage"
-
-
Norske Ultimovacs venter på topline resultatet fra fase II studiet INITIUM. Det er lovet at resultaterne kommer her i marts 2024.
I det norsk investor-miljø er der mange som venter med spændning på resultaterne. Dette gælder lige fra større investorer i selskabet til mange små-aktionærer. Men hvorfo det? - Det lkræver en forklaring https://www.proinvestor.com/boards/119174/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind